Adrian Rawcliffe, Adaptimmune CEO
May 19, 2021 05:00 PM EDTUpdated May 19, 09:16 PM
R&D

#AS­CO21: Adap­ti­m­mune gives first glimpse at piv­otal da­ta for what they hope will be first ap­proved TCR

Jason Mast

Editor

Six years af­ter Adap­ti­m­mune hauled what at the time was one of biotech’s largest-ever IPOs, CEO Adri­an Raw­cliffe thinks they’re fi­nal­ly on track to get …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

J&J takes 340B fight with fed­er­al gov­ern­ment to court

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Ex­clu­sive: Flag­ship names two CEO-part­ners to lead Va­lo Health, Apri­ori Bio

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times